Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy With Reduced Versus Standard Dose of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (REBEL)

NCT07748689 is registered in ClinicalTrials.gov with Polish Myeloma Consortium as lead sponsor.

NCT NCT07748689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Randomized Study to Evaluate Safety and Efficacy of MRD-guided Therapy With Reduced Versus Standard Dose of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (REBEL)
Lead sponsor
Polish Myeloma Consortium
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2033
Enrollment
228 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed / refractory multiple myeloma